Adults 3 to 12, any sex, with Hookworm Infections. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Geometric Mean Egg Reduction Rate (ERR) of the Two Formulations of Mebendazole Against HookwormPrimary· Baseline (before treatment) and sometime between 14 and 21 days post-treatment
Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. The egg reduction rate (ERR) is calculated as follows: ERR = (1-(geometric mean EPG at follow-up/geometric mean EPG at baseline))\*100). Note: in contrast to the publication the "outcome measure" entry mask requires the complementary percentage: (geometric mean at follow-up/geometric mean at baseline)\*100).
Group
Value
95% CI
Chewable Tablet of Mebendazole
68.5
60.4 – 75.3
Swallowable Tablet of Mebendazole
70.8
63.5 – 76.7
Cure Rate (CR) of Mebendazole Against HookwormSecondary· Baseline (before treatment) and sometime between 14 and 21 days post-treatment
Cure rates (CRs) will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment.
Group
Value
95% CI
Chewable Tablet of Mebendazole
12.7
8.4 – 18.2
Swallowable Tablet of Mebendazole
11.2
7.2 – 16.5
CR of Both Mebendazole Regimens Against Trichuris TrichiuraSecondary· Baseline (before treatment) and sometime between 14 and 21 days post-treatment
Cure rates (CRs) will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment.
Group
Value
95% CI
Chewable Tablet of Mebendazole
9.8
Swallowable Tablet of Mebendazole
7.3
Geometric ERR of Both Mebendazole Formulations Against Trichuris TrichiuraSecondary· Baseline (before treatment) and sometime between 14 and 21 days post-treatment
Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. The egg reduction rate (ERR) is calculated as follows: ERR = (1-(geometric mean EPG at follow-up/geometric mean EPG at baseline))\*100). Note: in contrast to the publication the "outcome measure" entry mask requires the complementary percentage: (geometric mean at follow-up/geometric mean at baseline)\*100).
Group
Value
95% CI
Chewable Tablet of Mebendazole
73.3
65.7 – 79.4
Swallowable Tablet of Mebendazole
74.2
67.2 – 79.8
CR of Both Mebendazole Formulations Against Ascaris LumbricoidesSecondary· Baseline (before treatment) and sometime between 14 and 21 days post-treatment
Cure rates (CRs) will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment.
Group
Value
95% CI
Chewable Tablet of Mebendazole
95.3
Swallowable Tablet of Mebendazole
97.8
Geometric ERR of Both Mebendazole Formulations Against Ascaris Lumbricoides.Secondary· Baseline (before treatment) and sometime between 14 and 21 days post-treatment
Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. The egg reduction rate (ERR) is calculated as follows: ERR = (1-(geometric mean EPG at follow-up/geometric mean EPG at baseline))\*100). Note: in contrast to the publication the "outcome measure" entry mask requires the complementary percentage: (geometric mean at follow-up/geometric mean at baseline)\*100).
Group
Value
95% CI
Chewable Tablet of Mebendazole
99.9
Swallowable Tablet of Mebendazole
99.9
Arithmetic ERR of the Two Formulations of Mebendazole Against HookwormSecondary· Baseline (before treatment) and sometime between 14 and 21 days post-treatment
Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. The egg reduction rate (ERR) is calculated as follows: ERR = (1-(arithmetic mean EPG at follow-up/arithmetic mean EPG at baseline))\*100). Note: in contrast to the publication the "outcome measure" entry mask requires the complementary percentage: (arithmetic mean at follow-up/arithmetic mean at baseline)\*100).
Group
Value
95% CI
Chewable Tablet of Mebendazole
38.2
26.6 – 47.8
Swallowable Tablet of Mebendazole
28.1
8.5 – 44.3
Arithmetic ERR of Both Mebendazole Formulations Against Trichuris TrichiuraSecondary· Baseline (before treatment) and sometime between 14 and 21 days post-treatment
Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. The egg reduction rate (ERR) is calculated as follows: ERR = (1-(arithmetic mean EPG at follow-up/arithmetic mean EPG at baseline))\*100). Note: in contrast to the publication the "outcome measure" entry mask requires the complementary percentage: (arithmetic mean at follow-up/arithmetic mean at baseline)\*100).
Group
Value
95% CI
Chewable Tablet of Mebendazole
52.9
Swallowable Tablet of Mebendazole
50.9
Arithmetic ERR of Both Mebendazole Formulations Against Ascaris LumbricoidesSecondary· Baseline (before treatment) and sometime between 14 and 21 days post-treatment
Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. The egg reduction rate (ERR) is calculated as follows: ERR = (1-(arithmetic mean EPG at follow-up/arithmetic mean EPG at baseline))\*100). Note: in contrast to the publication the "outcome measure" entry mask requires the complementary percentage: (arithmetic mean at follow-up/arithmetic mean at baseline)\*100).
Group
Value
95% CI
Chewable Tablet of Mebendazole
98.7
Swallowable Tablet of Mebendazole
99.8
Adverse events — posted to ClinicalTrials.gov
Time frame: 3 hours and 24 hours post-treatment.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The rational of this study is to provide evidence on the safety and efficacy of a new chewable tablet of mebendazole compared to the standard tablet in preschool- and school-aged children infected with hookworm.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06720259 — Efficacy and Safety of Oxantel Pamoate in Children Infected With Trichuris Trichiura
· Phase 2
· completed
NCT04443049 — To Study the Effects of Addition of Mebendazole to Lenvatinib in Cirrhotics With Advanced Hepatocellular Carcinoma.
· NA
· unknown
NCT03278431 — Triple Combinations Against Hookworm Infections in Lao
· Phase 4
· completed
Other recruiting trials for Hookworm Infections
Currently open trials in the same condition.
NCT07145736 — Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical
· Phase 4
· recruiting
Other Swiss Tropical & Public Health Institute trials
Trials by the same sponsor.
NCT06606860 — Safety, Tolerability and PK of Single and Multiple Doses of Oxantel Pamoate Tablets
· Phase 1
· completed
NCT06373835 — Efficacy and Safety of Emodepside in Adults Infected With Strongyloidiasis Stercoralis
· Phase 2
· completed
NCT06304831 — Use of Facility Ratings to Improve Satisfaction With Heath Care for Children
· NA
· completed
NCT05644067 — Assessment of the Malaria Vaccine Candidate SumayaVac-1 in Healthy Adults Aged 18-45 Years Living in a Malaria Endemic C
· Phase 1
· completed
NCT06648603 — Citizen Action for Sustainable Dengue Control in Sub-Saharan Africa
· NA
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Swiss Tropical & Public Health Institute
Last refreshed: 20 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03995680.